Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

1 Jan 2023

Abstract excerpt

Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Surgical Treatments
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37744267
DOI: 10.32604/or.2023.030374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancerPMID 37744267Read ↗

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.Semantic proximity Read ↗

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features.Semantic proximity Read ↗

Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapiesSemantic proximity Read ↗

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Semantic proximity Read ↗

Genomic landscape of treatment refractory metastatic colorectal cancer.Semantic proximity Read ↗

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.Semantic proximity Read ↗

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Semantic proximity Read ↗

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.